Holger Woehrle.

Although product pipelines are drying up, the emergence of brand-new markets, coupled with the arrival of personalized medicine and other advances, present exciting opportunities for drugmakers. And, provided the unpredictable drug-development environment, analysts are keeping a watchful eyesight as a ‘tale of two CEOs’ unfolds at two top pharmaceutical firms. One leadership change appears to show a firm sticking to a carefully plotted training course. The other, a far more unexpected switch at the helm, reveals a pharmaceutical giant with a fluctuating business approach.